Emily J Hill1, Christopher G Goetz2, Glenn T Stebbins2, Randi Hagerman3,4, Bichun Ouyang2, Deborah A Hall2. 1. Department of Neurology Baylor College of Medicine Houston Texas USA. 2. Department of Neurological Sciences Rush University Medical Center Chicago Illinois USA. 3. University of California Davis Medical Investigation of Neurodevelopmental Disorders (MIND) Institute Sacramento California USA. 4. Department of Pediatrics University of California Davis Medical Center Sacramento California USA.
Abstract
BACKGROUND: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder characterized by intention tremor, cerebellar ataxia, and executive dysfunction in carriers of a CGG repeat expansion premutation (55-200 repeats) in the fragile X mental retardation 1 (FMR1) gene. Given reports of poor insight in FXTAS, we postulated that patients with FXTAS would be less likely to exhibit placebo response. OBJECTIVE: To analyze placebo response from the first randomized controlled trial in FXTAS that evaluated cognitive and motor outcomes after 1 year of treatment with memantine. METHODS: Data from the placebo arm of the first randomized controlled trial in FXTAS were analyzed. There were 2 coprimary outcomes. Based on studies in Parkinson's disease, placebo responders were defined as individuals with an improvement of at least 50% in the coprimary outcomes. Improvements of 20% and 30% served as secondary cutoff values based on the suggested magnitude of placebo response in other movement disorders. RESULTS: A total of 36 participants in the placebo group completed baseline and follow-up evaluations. The average age was 66 ± 7 years, and 60% were men. Average CGG repeat size was 86 ± 18. A total of 19 participants had stage 3 disease. Only 1 patient showed 50% improvement in both coprimary outcomes. At 30% and 20% improvement, there were 2 and 3 patients showing placebo response in the coprimary outcomes, respectively. CONCLUSIONS: Patients with FXTAS exhibited low rates of placebo response in a randomized controlled trial. Further studies on the relationship between baseline insight and placebo responsivity are applicable to FXTAS and other disorders exhibiting cognitive impairment.
BACKGROUND: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder characterized by intention tremor, cerebellar ataxia, and executive dysfunction in carriers of a CGG repeat expansion premutation (55-200 repeats) in the fragile X mental retardation 1 (FMR1) gene. Given reports of poor insight in FXTAS, we postulated that patients with FXTAS would be less likely to exhibit placebo response. OBJECTIVE: To analyze placebo response from the first randomized controlled trial in FXTAS that evaluated cognitive and motor outcomes after 1 year of treatment with memantine. METHODS: Data from the placebo arm of the first randomized controlled trial in FXTAS were analyzed. There were 2 coprimary outcomes. Based on studies in Parkinson's disease, placebo responders were defined as individuals with an improvement of at least 50% in the coprimary outcomes. Improvements of 20% and 30% served as secondary cutoff values based on the suggested magnitude of placebo response in other movement disorders. RESULTS: A total of 36 participants in the placebo group completed baseline and follow-up evaluations. The average age was 66 ± 7 years, and 60% were men. Average CGG repeat size was 86 ± 18. A total of 19 participants had stage 3 disease. Only 1 patient showed 50% improvement in both coprimary outcomes. At 30% and 20% improvement, there were 2 and 3 patients showing placebo response in the coprimary outcomes, respectively. CONCLUSIONS: Patients with FXTAS exhibited low rates of placebo response in a randomized controlled trial. Further studies on the relationship between baseline insight and placebo responsivity are applicable to FXTAS and other disorders exhibiting cognitive impairment.
Authors: Esther Cubo; Miguel González; Inés del Puerto; Justo Garcia de Yébenes; Olga Fernández Arconada; José María Trejo Gabriel y Galán Journal: Mov Disord Date: 2011-12-09 Impact factor: 10.338
Authors: Melina C Ortigas; James A Bourgeois; Andrea Schneider; John Olichney; Danh V Nguyen; Jennifer B Cogswell; Deborah A Hall; Randi J Hagerman Journal: J Clin Psychopharmacol Date: 2010-10 Impact factor: 3.153
Authors: Andreea L Seritan; Danh V Nguyen; Yi Mu; Flora Tassone; James A Bourgeois; Andrea Schneider; Jennifer B Cogswell; Kylee R Cook; Maureen A Leehey; Jim Grigsby; John M Olichney; Patrick E Adams; Wendi Legg; Lin Zhang; Paul J Hagerman; Randi J Hagerman Journal: J Clin Psychiatry Date: 2014-03 Impact factor: 4.384
Authors: Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans Journal: Mov Disord Date: 2008-04-15 Impact factor: 10.338
Authors: Deborah A Hall; Glenn T Stebbins; Sebastien Jacquemont; Elizabeth Berry-Kravis; Christopher G Goetz; Randi Hagerman; Lin Zhang; Maureen A Leehey Journal: Mov Disord Clin Pract Date: 2019-01-22